medicalxpress - A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.
#healthcare #publichealth #governmentpolicy #biotech #medicaldevices #oncology
Thursday, February 26, 2026, 7:24 pm / permalink 19851 / 7 stories in 12 days
Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...
#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #drugdevelopment
Thursday, February 26, 2026, 7:23 am / permalink 19788 / 12 stories in 13 days
Judge orders Leapfrog to remove safety grades for five Florida hospitals 3 stories in 21.1 hours
Daily multivitamin slows epigenetic aging in randomized COSMOS analysis 4 stories in 40.1 hours
Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity 6 stories in 54.1 hours
White House briefing triggered rapid drops in acetaminophen use in ERs 2 stories in 58.1 hours
MUSC Health buys large South Carolina multispecialty practice for $111M 4 stories in 58.1 hours
Eli Lilly launches Employer Connect to broaden GLP‑1 coverage 16 stories in 83.2 hours
Analysis finds small patient group drives majority of admissions and costs 2 stories in 83.2 hours
Springing forward worsens sleep and sparks health complaints 8 stories in 87.2 hours
Cancer Grand Challenges awards five teams bold funding for cancer research 67 stories in 94.2 hours
Belzutifan combinations highlighted at ASCO GU improve RCC outcomes 3 stories in 96.2 hours
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.
Bluesky: